Deutsch English Français

Contact

EP2090176

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

Latvia joins the Federated Register
Click here for more information on the Federated Register.

2025-04-16

More...

Extract from the Register of European Patents

EP About this file: EP2090176

EP2090176 - Postprandial hyperglycemia-improving agent [Right-click to bookmark this link]
Status	No opposition filed within time limit Status updated on 28.02.2020 Database last updated on 26.04.2025
Former	The patent has been granted Status updated on 22.03.2019
Former	Grant of patent is intended Status updated on 05.12.2018
Former	Examination is in progress Status updated on 24.11.2017
Most recent event Tooltip	28.02.2020	No opposition filed within time limit	published on 01.04.2020 [2020/14]
Applicant(s)	For all designated states Kao Corporation 14-10, Nihonbashi Kayabacho 1-chome Chuo-Ku Tokyo 103-8210 / JP
	[2009/34]
Inventor(s)	01 / Osaki, Noriko c/o Kao Corp. Research Laboratories 2606, Akabane, Ichikaimache Haga-gun Tochigi 321-3497 / JP
	02 / Onizawa, Koji c/o Kao Corp. Research Laboratories 2606, Akabane, Ichikaimache Haga-gun Tochigi 321-3497 / JP
	03 / Shimotoyodome, Akira c/o Kao Corp. Research Laboratories 2606, Akabane, Ichikaimache Haga-gun Tochigi 321-3497 / JP
	[2019/17]
Former [2009/34]	01 / Osaki, Noriko c/o Kao Corporation Research Laboratories 2606, Ak Tochigi 321-3497 / JP
	02 / Onizawa, Koji c/o Kao Corporation Research Laboratories 2606, Ak Tochigi 321-3497 / JP
	03 / Shimotoyodome, Akira c/o Kao Corporation Research Laboratories 2606, Ak Tochigi 321-3497 / JP
Representative(s)	Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE
	[2019/17]
Former [2009/35]	HOFFMANN EITLE Patent- und Rechtsanwälte Arabellastrasse 4 81925 München / DE
Former [2009/34]	HOFFMANN EITLE Patent-und Rechtsanwälte Arabellastrasse 4 81925 München / DE
Application number, filing date	09152656.6	12.02.2009
	[2009/34]
Priority number, date	JP20080031832	13.02.2008 Original published format: JP 2008031832
	JP20090000781	06.01.2009 Original published format: JP 2009000781
	[2009/34]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	EP2090176
	Date:	19.08.2009
	Language:	EN
	[2009/34]
	Type:	B1 Patent specification
	No.:	EP2090176
	Date:	24.04.2019
	Language:	EN
	[2019/17]
Search report(s)	(Supplementary) European search report - dispatched on:	EP	28.04.2009
Classification	IPC:	A23D7/00, A23D9/00, A61K31/20, A61P3/10, A23D9/013, A61K31/201	[2018/49]
	CPC:	A23D9/013 (EP,US); A61K31/201 (EP,US); A61P3/04 (EP); A61P3/10 (EP)
	Former IPC [2009/34]	A23D7/00, A23D9/00, A61K31/20, A61P3/10
Designated contracting states	DE, FR, GB [2019/17]
Former [2010/17]	DE, FR, GB
Former [2009/34]	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR
Title	German:	Wirkstoff zur Verbesserung der postprandialen Hyperglykämie	[2009/34]
	English:	Postprandial hyperglycemia-improving agent	[2009/34]
	French:	Agent d'amélioration d'hyperglycémie postprandiale	[2019/01]
	Former [2009/34]	Agent d'amélioration d'hyperglycémie postprandiale
Examination procedure	03.11.2009	Amendment by applicant (claims and/or description)
	08.01.2010	Examination requested [2010/08]
	20.02.2010	Loss of particular rights, legal effect: designated state(s)
	29.03.2010	Despatch of communication of loss of particular rights: designated state(s) AT, BE, BG, CH, CY, CZ, DK, EE, ES, FI, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR
	28.10.2010	Despatch of a communication from the examining division (Time limit: M06)
	28.04.2011	Reply to a communication from the examining division
	22.05.2012	Despatch of a communication from the examining division (Time limit: M02)
	01.08.2012	Reply to a communication from the examining division
	05.02.2014	Cancellation of oral proceeding that was planned for 24.02.2014
	14.02.2014	Despatch of a communication from the examining division (Time limit: M06)
	24.02.2014	Date of oral proceedings (cancelled)
	25.08.2014	Reply to a communication from the examining division
	18.02.2016	Despatch of a communication from the examining division (Time limit: M04)
	16.06.2016	Reply to a communication from the examining division
	14.11.2017	Despatch of a communication from the examining division (Time limit: M04)
	19.02.2018	Reply to a communication from the examining division
	03.05.2018	Despatch of a communication from the examining division (Time limit: M04)
	06.08.2018	Reply to a communication from the examining division
	06.12.2018	Communication of intention to grant the patent
	18.03.2019	Fee for grant paid
	18.03.2019	Fee for publishing/printing paid
	18.03.2019	Receipt of the translation of the claim(s)
Divisional application(s)	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 28.10.2010
Opposition(s)	27.01.2020	No opposition filed within time limit [2020/14]
Fees paid	Renewal fee
	23.02.2011	Renewal fee patent year 03
	27.02.2012	Renewal fee patent year 04
	20.02.2013	Renewal fee patent year 05
	18.02.2014	Renewal fee patent year 06
	18.02.2015	Renewal fee patent year 07
	25.02.2016	Renewal fee patent year 08
	27.02.2017	Renewal fee patent year 09
	21.02.2018	Renewal fee patent year 10
	18.02.2019	Renewal fee patent year 11
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[X]WO2007046441 (KAO CORP [JP], et al) [X] 1-3 * page 3, lines 6-17 * * page 3, lines 27-30 * * page 3, lines 36-38 * * page 8, lines 20-29 * * page 10; table 1 * * page 15; table 15 *;
		[X]EP1946651 (KAO CORP [JP]) [X] 1-3;
		[X]US2003198727 (KOIKE SHIN [JP], et al) [X] 1-3 * page 6; tables 1,3 * * page 11, column R, paragraph 3 *;
		[X]EP1407674 (KAO CORP [JP]) [X] 1-3 * page 2, lines 10-12 * * claims 1,2 *;
		[X]US2004062847 (KOIKE SHIN [JP], et al) [X] 1-3 * page 1, column R, paragraph 4 * * page 2, column L, paragraph 4 * * page 4, column L, paragraph 4 * * page 5; table 1 * * claims 1,16 *;
		[A]US2005123667 (SAKUMA TADASHI [JP], et al) [A] 1-3 * page 5; table 1 *;
		[PA] - MORITA O ET AL, "Effects of dietary diacylglycerol oil on embryo/fetal development in rats", FOOD AND CHEMICAL TOXICOLOGY, PERGAMON, GB, vol. 46, no. 7, ISSN 0278-6915, (20080701), pages 2510 - 2516, (20080412), XP022708014 [PA] 1-3 * page 2511; table 1 * DOI: http://dx.doi.org/10.1016/j.fct.2008.04.004
	Examination	- TOMONOBU K ET AL, "Dietary diacylglycerol in a typical meal suppresses postprandial increases in serum lipid levels compared with dietary triacylglycerol", NUTRITION, ELSEVIER INC, US, vol. 22, no. 2, ISSN 0899-9007, (20060201), pages 128 - 135, (20060201), XP027974108
		- TADA N ET AL, "Effects of diacylglycerol ingestion on postprandial hyperlipidemia in diabetes", CLINICA CHIMICA ACTA, ELSEVIER BV, AMSTERDAM, NL, vol. 353, no. 1-2, ISSN 0009-8981, (20050301), pages 87 - 94, (20050301), XP027648960
		- Hidekatsu Yanai ET AL, "Effects of Diacylglycerol on Glucose, Lipid Metabolism, and Plasma Serotonin Levels in Lean Japanese", Obesity, (20080101), vol. 16, no. 1, doi:10.1038/oby.2007.46, ISSN 1930-7381, pages 47 - 51, XP055100413 DOI: http://dx.doi.org/10.1038/oby.2007.46
		- TAGUCHI H ET AL, "Double-blind controlled study on the effects of dietary diacylglycerol on postprandial serum and chylomicron triacylglycerol responses in healthy humans.", JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION 2000 NOV-DEC, (200011), vol. 19, no. 6, ISSN 0731-5724, pages 789 - 796, XP009175952 DOI: http://dx.doi.org/10.1080/07315724.2000.10718079
		- MORI Y ET AL, "Dietary diacylglycerol reduces postprandial hyperlipidemia and ameliorates glucose intolerance in Otsuka Long-Evans Tokushima Fatty (OLETF) rats", NUTRITION, ELSEVIER INC, US, vol. 21, no. 9, ISSN 0899-9007, (20050901), pages 933 - 939, (20050901), XP027768645
		- J. Tuomilehto, "Point: A Glucose Tolerance Test Is Important for Clinical Practice", DIABETES CARE, US, (20021001), vol. 25, no. 10, doi:10.2337/diacare.25.10.1880, ISSN 0149-5992, pages 1880 - 1882, XP055247783 DOI: http://dx.doi.org/10.2337/diacare.25.10.1880
		- J. J. MEIER ET AL, "Excess glycaemic excursions after an oral glucose tolerance test compared with a mixed meal challenge and self-measured home glucose profiles: is the OGTT a valid predictor of postprandial hyperglycaemia and vice versa?", DIABETES, OBESITY AND METABOLISM, (20090301), vol. 11, no. 3, doi:10.1111/j.1463-1326.2008.00922.x, ISSN 1462-8902, pages 213 - 222, XP055248017 DOI: http://dx.doi.org/10.1111/j.1463-1326.2008.00922.x
	by applicant	JP2003002835
		JP2001064170
		JP2001247457
		JP2007045789
		- DIABETES CARE, (1999), vol. 22, pages 920 - 924
		- ARCH INTERN MED., (2001), vol. 161, pages 397 - 405
		- AM J PHYSIOL ENDOCRINOL METAB., (2001), vol. 281, pages 924 - 930
		- DIABETES CARE., (2001), vol. 24, no. 4, pages 775 - 778
		- J CLIN INVEST., (1988), vol. 81, no. 2, pages 442 - 448
		- J AM COL NUTR., (2000), vol. 19, no. 6, pages 789 - 796
		- CHEMISTRY AND BIOLOGY, (1983), vol. 21, page 179

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.32; 35p